 |
PTC Therapeutics Announces Achievement of Milestone in BMI1 Collaboration with the Wellcome Trust
Mar 2, 2011
|
8.6 KB |
| |
SOUTH PLAINFIELD, NJ – March 2, 2011 – PTC Therapeutics, Inc. (PTC) today announced that it has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers. The research marks a milestone in PTC's collaboration with the Wellcome ...
|
|
PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
Feb 1, 2011
|
8.5 KB |
| |
SOUTH PLAINFIELD, NJ AND HACKENSACK, NJ – FEBRUARY 1, 2011 – PTC Therapeutics, Inc. (PTC) and Parent Project Muscular Dystrophy (PPMD) today announced an expansion of their collaboration to discover new treatments for patients with Duchenne/Becker muscular dystrophy (DBMD). PPMD has awarded PTC a $250,000 grant, with the potential of add...
|
|
PTC THERAPEUTICS' PRESIDENT AND CEO ELECTED AAAS FELLOW
Jan 19, 2011
|
7.5 KB |
| |
SOUTH PLAINFIELD, NJ – January 19, 2011 – Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science. AAAS Fellows are chosen by their peers and r...
|
|
PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
Dec 21, 2010
|
11.0 KB |
| |
SOUTH PLAINFIELD, NJ – DECEMBER 21, 2010 – PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF).The 48-week study is designed to determine whether ataluren can improve lung function...
|
|
Observational Data from One-Year Follow-up Study Validate Six-Minute Walk Distance as an Outcome Measure in Duchenne and Becker Muscular Dystrophy
Dec 1, 2010
|
10.9 KB |
| |
SOUTH PLAINFIELD, NJ – December 1, 2010 – Data published in the December issue of the medical journal Muscle and Nerve confirm the utility of six-minute walk distance (6MWD) as a clinically meaningful endpoint in dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (DBMD). The data showed that boys with...
|
|
PTC Publishes Results From Phase 2 Study of Ataluren in Children with Cystic Fibrosis
Nov 15, 2010
|
11.9 KB |
| |
SOUTH PLAINFIELD, NJ – November 15, 2010 – PTC Therapeutics, Inc. today announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine. The published data show that treatment with ataluren, an investig...
|
|
PTC Therapeutics Initiates Phase 2 Clinical Trial of Ataluren in Patients with Methylmalonic Acidemia
Oct 26, 2010
|
10.8 KB |
| |
SOUTH PLAINFIELD, NJ – October 26, 2010 – PTC Therapeutics, Inc. today announced that it is expanding the development of ataluren, an investigational new drug, with the initiation of a Phase 2 clinical trial in nonsense mutation methylmalonic acidemia (nmMMA). MMA is a rare genetic disorder caused by deficiencies of crucial metabolic enz...
|
|
PIVOTAL DATA PRESENTED AT THE WORLD MUSCLE SOCIETY CONGRESS SUGGEST ATALUREN SLOWS THE LOSS OF WALKING ABILITY IN PATIENTS WITH NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY
Oct 15, 2010
|
12.9 KB |
| |
SOUTH PLAINFIELD, NJ – October 15, 2010 – PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD)....
|
|
PTC THERAPEUTICS AWARDED $1.6 MILLION FDA ORPHAN DRUG GRANT TO SUPPORT AN ONGOING PHASE 3 STUDY IN CYSTIC FIBROSIS
Sep 21, 2010
|
9.8 KB |
| |
SOUTH PLAINFIELD, NJ – SEPTEMBER 21, 2010 – PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF). The g...
|
|
PTC THERAPEUTICS AWARDED $5.4 MILLION GRANT FROM THE WELLCOME TRUST
Jun 7, 2010
|
9.5 KB |
| |
SOUTH PLAINFIELD, NJ – June 7, 2010 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $5.4 million Seeding Drug Discovery (SDD) Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers. Bmi-1 has been implicated in a wide variety...
|
|
PTC THERAPEUTICS AND GENZYME CORPORATION ANNOUNCE PRELIMINARY RESULTS FROM THE PHASE 2B CLINICAL TRIAL OF ATALUREN FOR NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY
Mar 3, 2010
|
12.3 KB |
| |
SOUTH PLAINFIELD, NJ and CAMBRIDGE, MA – March 03, 2010 – PTC Therapeutics, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD). The primary endpoint of chan...
|
|
PTC THERAPEUTICS ANNOUNCES ADDITIONAL STUDY OF ATALUREN IN PATIENTS WITH ADVANCED NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY
Jan 19, 2010
|
12.3 KB |
| |
SOUTH PLAINFIELD, NJ – January 19, 2010 – PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently. This trial is evaluating the best...
|
|
PTC THERAPEUTICS CLOSES $50 MILLION FINANCING
Dec 22, 2009
|
7.8 KB |
| |
SOUTH PLAINFIELD, NJ – December 22, 2009 – PTC Therapeutics, Inc. (PTC) today announced the completion of a $50 million financing. The round was led by The Column Group – a new investor – and existing investor Delphi Ventures. The co-lead investors were joined by current investors Credit Suisse First Boston, HBM BioVentures, N...
|
|
DATA PUBLISHED IN MUSCLE AND NERVE VALIDATES THE SIX-MINUTE WALK TEST AS AN OUTCOME MEASURE IN DUCHENNE MUSCULAR DYSTROPHY
Dec 8, 2009
|
11.1 KB |
| |
SOUTH PLAINFIELD, NJ – December 8, 2009 – Data published online in the medical journal Muscle and Nerve support the use of the six-minute walk test (6MWT) as an outcome measure in PTC Therapeutics, Inc.'s ongoing registration-directed clinical trial of ataluren in patients with nonsense mutation Duchenne/Becker muscular dystrophy (nmDMD/B...
|
|
PTC Therapeutics Receives $1 Million Challenge Grant Award From The National Institutes of Health
Dec 2, 2009
|
8.5 KB |
| |
SOUTH PLAINFIELD, NJ – December 2, 2009 – PTC Therapeutics, Inc. (PTC) today announced the receipt of a $1 million Challenge Grant award from the National Heart, Lung, and Blood Institute (NHLBI) as part of the National Institutes of Health (NIH). According to the NIH, 840 grants were awarded out of the approximately 20,000 applications ...
|
|
PTC THERAPEUTICS INITIATES PHASE 2 CLINICAL TRIAL OF ATALUREN (PTC124®) IN PATIENTS WITH HEMOPHILIA
Oct 26, 2009
|
12.4 KB |
| |
SOUTH PLAINFIELD, NJ - October 26, 2009 - PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB). Hemophilia is a rare and debilitating gene...
|
|
PTC THERAPEUTICS INITIATES REGISTRATION-DIRECTED PHASE 3 TRIAL OF ATALUREN IN CYSTIC FIBROSIS
Sep 10, 2009
|
13.4 KB |
| |
SOUTH PLAINFIELD, NJ – September 10, 2009 – PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124®), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF). Patients with CF lack adequate levels of the cystic fibrosis transmembrane con...
|
|
PTC THERAPEUTICS ANNOUNCES DRUG DISCOVERY COLLABORATION WITH ROCHE
Sep 2, 2009
|
8.2 KB |
| |
SOUTH PLAINFIELD, N.J., September 2, 2009 – PTC Therapeutics, Inc. (PTC) today announced an exclusive research collaboration and licensing agreement with Roche for the development of orally bioavailable small molecules utilizing PTC's technology called Gene Expression Modulation by Small-molecules (GEMS™). The collaboration focuses initi...
|
|
PTC THERAPEUTICS ANNOUNCES CELGENE EXERCISED OPTION TO DRUG DISCOVERY COLLABORATION
Sep 2, 2009
|
7.7 KB |
| |
SOUTH PLAINFIELD, NJ – September 2, 2009 – PTC Therapeutics, Inc. (PTC) today announced that Celgene Corporation has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC's GEMSTM (Gene Expression Modulation by Small-molecules) technology. In Sept...
|
|
PTC THERAPEUTICS ANNOUNCES ACHIEVEMENT OF MAJOR MILESTONE IN SCHERING-PLOUGH HEPATITIS C COLLABORATION
Aug 10, 2009
|
9.7 KB |
| |
SOUTH PLAINFIELD, NJ – August 10, 2009 – PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) inf...
|
|
|
